Codex DNA, Inc. (DNAY)

NASDAQ: DNAY · IEX Real-Time Price · USD
1.34
-0.04 (-2.90%)
Dec 5, 2022 4:00 PM EST - Market closed
-2.9%
Market Cap 40.74M
Revenue (ttm) 21.04M
Net Income (ttm) -52.83M
Shares Out 29.52M
EPS (ttm) -1.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 67,679
Open 1.43
Previous Close 1.38
Day's Range 1.34 - 1.43
52-Week Range 1.34 - 11.32
Beta n/a
Analysts Buy
Price Target 6.63 (+394.8%)
Earnings Date Nov 8, 2022

About DNAY

Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building bloc... [Read more]

Industry Medical Devices
IPO Date Jun 18, 2021
Employees 212
Stock Exchange NASDAQ
Ticker Symbol DNAY
Full Company Profile

Financial Performance

In 2021, Codex DNA's revenue was $11.04 million, an increase of 67.93% compared to the previous year's $6.58 million. Losses were -$38.96 million, 116.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for DNAY stock is "Buy." The 12-month stock price forecast is 6.63, which is an increase of 394.78% from the latest price.

Price Target
$6.63
(394.78% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Codex DNA (DNAY) Reports Q3 Loss, Tops Revenue Estimates

Codex DNA (DNAY) delivered earnings and revenue surprises of 12.50% and 25.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

Telesis Bio Inc. Reports Third Quarter 2022 Financial Results

-- Record revenue of $6.7M in 3QFY22; Increase of 140% over $2.8M 3QFY 2021

3 weeks ago - GlobeNewsWire

Telesis Bio to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 8

SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2022 fin...

1 month ago - GlobeNewsWire

Telesis Bio and Cellibre Announce Collaboration to Optimize Development of Future BioXp® DBC instrument

Agreement will allow researchers to streamline development of on-demand and automated production of CRISPR-Cas9 guide RNA Agreement will allow researchers to streamline development of on-demand and auto...

1 month ago - GlobeNewsWire

Codex DNA Announces Plan to Change Corporate Name to Telesis Bio

Novel name reflects expansion of capabilities and solutions Novel name reflects expansion of capabilities and solutions

1 month ago - GlobeNewsWire

Codex DNA Expands Application of Proprietary Error Correction Technology

New BioXp® Error Corrected Libraries have two-fold increase in sequence fidelity New BioXp® Error Corrected Libraries have two-fold increase in sequence fidelity

2 months ago - GlobeNewsWire

Codex DNA Showcases Next Generation Automated Synthetic Biology Workstation at World of Technology & Science in Utrec...

BioXp™ 9600 system – a fully automated, high-throughput benchtop instrument for synthetic biology workflows – nominated for prestigious World of Laboratory Tech Award BioXp™ 9600 system – a fully automa...

2 months ago - GlobeNewsWire

Codex DNA Debuts Next-Generation Automated Synthetic Biology Workstation

BioXp™ 9600 system – a fully automated, high-throughput benchtop instrument for synthetic biology workflows – empowers scientists to accelerate discovery of new vaccines and biologics BioXp™ 9600 system...

2 months ago - GlobeNewsWire

Codex DNA (DNAY) Could Find Support Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Codex DNA (DNAY), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisio...

3 months ago - Zacks Investment Research

Codex DNA (DNAY) Reports Q2 Loss, Tops Revenue Estimates

Codex DNA (DNAY) delivered earnings and revenue surprises of 1.96% and 22.94%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Codex DNA Reports Second Quarter 2022 Financial Results

SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the second quarter ended June...

3 months ago - GlobeNewsWire

Codex DNA to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022

SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its second quarter 2022 finan...

4 months ago - GlobeNewsWire

Codex DNA to Present at the 2022 Jefferies Healthcare Conference

SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that Todd R. Nelson, PhD, the company's chief exec...

6 months ago - GlobeNewsWire

Codex DNA Showcases Automated Synthetic Biology Solutions for Accelerating Discovery Workflows at the Antibody Engine...

BioXp™ system and RapidAMP™ cell-free DNA kit rapidly accelerate antibody discovery pipelines by addressing critical bottlenecks associated with lead candidate gene synthesis, cloning, and scale-up

6 months ago - GlobeNewsWire

Codex DNA Reports First Quarter 2022 Financial Results

SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the first quarter ended March ...

6 months ago - GlobeNewsWire

Codex DNA to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022

SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its first quarter 2022 financi...

7 months ago - GlobeNewsWire

Codex DNA Unveils Automated Synthetic Biology Solutions for Antibody and Protein Engineering of Biotherapeutic Target...

BioXp™ system and RapidAMP™ cell-free DNA kit allow scientists to synthesize, clone, and amplify antibody-variable regions based on a digital sequence input with a single push of a button BioXp™ system ...

7 months ago - GlobeNewsWire

Codex DNA Demonstrates End-to-End Workflow for Storing and Retrieving Data in Synthetic DNA

Proof-of-concept studies go beyond typical DNA data storage projects to ensure high-fidelity data recovery within an automated synthetic biology workflow Proof-of-concept studies go beyond typical DNA d...

7 months ago - GlobeNewsWire

Codex DNA Demonstrates Simple, Scalable, and Cell-Free Approach to Rapid mRNA Vaccine Design and Development at World...

Automated benchtop BioXp™ system offers significant quality, time, and cost advantages for DNA and mRNA synthesis compared to alternative options Automated benchtop BioXp™ system offers significant qual...

7 months ago - GlobeNewsWire

Codex DNA to Showcase Innovative SOLA Enzymatic DNA Synthesis Technology and Automated Benchtop BioXp System at SynBi...

SOLA approach has the potential to be more accurate, scalable, and cost-effective compared to traditional chemical synthesis and alternative enzymatic techniques for constructing DNA SOLA approach has t...

7 months ago - GlobeNewsWire

Codex DNA Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Guidance

SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the fourth quarter and year ...

8 months ago - GlobeNewsWire

Codex DNA Announces Registration and Webcast Information for Upcoming R&D Webinar on March 29, 2022

SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced details for its first Investor R&D Webinar. Manag...

9 months ago - GlobeNewsWire

Codex DNA to Report Fourth Quarter 2021 Financial Results on Tuesday, March 22, 2022

SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its fourth quarter 2021 fina...

9 months ago - GlobeNewsWire

Codex DNA to Present at the Cowen 42nd Annual Healthcare Conference

SAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that Todd R. Nelson, PhD, the company's chief exec...

9 months ago - GlobeNewsWire

Codex DNA to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

SAN DIEGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that members of its management team will be partic...

9 months ago - GlobeNewsWire